CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Activation of the complement system on the cell surface results in the insertion of pore forming membrane attack complexes (MAC, C5b-9). In order to protect themselves from the complement attack, the cells express several regulatory molecules, including the terminal complex regulator CD59 that inhibits assembly of the large MACs by inhibiting the insertion of additional C9 molecules into the C5b-9 complex. Using the whole cell patch clamp method, we were able to measure accumulation of homologous MACs in the membrane of CD59(-) human B-cells, which formed non-selective ion channels with a total conductance of 360 +/- 24 pS as measured at the beginning of the steady-state phase of the inward currents. C5b-8 and small-size MAC (MAC containing only a single C9) can also form ion channels. Nevertheless, in CD59(+) human B-cells in spite of small-size MAC formation, an ion current could not be detected. In addition, restoring CD59 to the membrane of the CD59(-) cells inhibited the serum-evoked inward current. The ion channels formed by the small-size MAC were therefore sealed, indicating that CD59 directly interfered with the pore formation of C5b-8 as well as that of small-size C5b-9. These results offer an explanation as to why CD59-expressing cells are not leaky in spite of a buildup of homologous C5b-8 and small-size MAC. Our experiments also confirmed that ion channel inhibition by CD59 is subject to homologous restriction and that CD59 cannot block the conductivity of MAC when generated by xenogenic (rabbit) serum.
Farkas
Imre
I
Department of Molecular Biology, Nagoya City University School of Medicine, Nagoya 467-8601, Japan.
Baranyi
Lajos
L
Ishikawa
Yasushige
Y
Okada
Noriko
N
Bohata
Csaba
C
Budai
Denes
D
Fukuda
Atsuo
A
Imai
Masaki
M
Okada
Hidechika
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D018957:CD59 Antigens / Q000494:pharmacology*; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003186:Complement C9 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015938:Complement Membrane Attack Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003165:Complement System Proteins / Q000187:drug effects* / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D007473:Ion Channels / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D011817:Rabbits
D000911:Antibodies, Monoclonal; D018957:CD59 Antigens; D003186:Complement C9; D015938:Complement Membrane Attack Complex; D007473:Ion Channels; C042295:complement C5b-8 complex; D003165:Complement System Proteins